Indeed, several drugs targeting IL6 and its receptor (IL6R) currently used for the treatment of autoimmune or inflammatory disorders (Choy et al., 2020) may be further investigated for potential drug repurposing strategies in the management of PD and other neurodegenerative pathologies. This evidence concerns the gene IL6R and Parkinson disease.